Adverse Survival Signal Leads G1 to Stop Pivotal Test in Colorectal Cancer

Adverse Survival Signal Leads G1 to Stop Pivotal Test in Colorectal Cancer

G1 Therapeutics’ approach to cancer does not kill tumors. Instead, the biotech’s drug, trilaciclib, protects bone marrow from the damaging effects of chemotherapy, reducing the duration and severity of the problems that can limit the use of this cancer treatment. Since trilaciclib’s initial approval insmall cell lung cancer, G1 has pursued more clinical trials that could support expanding the drug to other cancers. Colorectal cancer will no longer be one of them.
On Monday, G1 reported preliminary data showing that the placebo group outperformed the trilaciclib arm in helping patients live longer. G1 said it has decided to stop the colorectal cancer…

Continue Reading
Virtual care enables BrightView Health to increase outpatient access

Virtual care enables BrightView Health to increase outpatient access

BrightView Health, a behavioral health facility that specializes in addiction treatment and substance abuse, already was using telehealth when the COVID-19 pandemic and associated response happened. The organization mostly was using telehealth between its various locations.THE PROBLEM
However, BrightView did not have a secure communications platform to engage with patients either synchronously or asynchronously.
“So, the pandemic and the lockdowns created some potential gaps in access to care that we needed to predict and fill,” said Navdeep S. Kang, chief clinical officer at BrightView Health and a fellow with the Obama Foundation. “We looked at several platforms to implement secure communications.
“We were specifically interested…

Continue Reading
Addressing Evolving Health Information Technology Needs in Pediatric Care: Neonatal Abstinence Syndrome (NAS) Informational Resource (IR)

Addressing Evolving Health Information Technology Needs in Pediatric Care: Neonatal Abstinence Syndrome (NAS) Informational Resource (IR)

Hot off the presses, the Pediatric Health Information Technology: Neonatal Abstinence Syndrome Informational Resource (NAS IR) [PDF – 808 KB] is a new resource from ONC to support pediatric care and practice settings specific to neonatal abstinence syndrome. The NAS IR builds upon prior efforts included in the ONC Pediatric Health Information Technology Informational Resources (IR) for health IT developers and for health care providers, and includes information about the implementation of health IT and its use as part of delivering health care to infants experiencing withdrawal after maternal exposure to opioids and other substances during pregnancy. This is the third…

Continue Reading